ProCE Banner Activity

Phase III BELLINI: Updated Results With Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Venetoclax plus bortezomib/dexamethasone was selectively associated with favorable survival outcomes in patients with R/R myeloma and the t(11;14) cytogenetic marker in this updated study analysis.

Released: June 02, 2020

Expiration: June 01, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono